✦ LIBER ✦

Peripherial arterial disease and long-term risk of dementia: The role of vascular injury in diabetes

✍ Scribed by Lieza Exalto; Geert Jan Biessels; Charles Quesenberry; Rachel Whitmer

Book ID: 118468797
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 57 KB
Volume: 8
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2012.05.895

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gender-specific midlife dementia risk: T

Gender-specific midlife dementia risk: The differential role of long-term vascular risk factors

✍ Lieza Exalto; Charles Quesenberry; Geert Jan Biessels; Jufen Zhou; Rachel Whitme 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Heavy Smoking in Midlife and Long-term R

Heavy Smoking in Midlife and Long-term Risk of Alzheimer Disease and Vascular Dementia

✍ Rusanen, Minna; Kivipelto, Miia; Quesenberry, Charles P.; Zhou, Jufen; Whitmer, 📂 Article 📅 2011 🏛 American Medical Association 🌐 English ⚖ 133 KB

Diabetes and Peripheral Vascular Disease

Diabetes and Peripheral Vascular Disease || The Role of Endovascular Therapy in Peripheral Arterial Disease

✍ Shrikhande, Gautam V.; McKinsey, James F. 📂 Article 📅 2012 🏛 Humana Press ⚖ 439 KB

Vascular dementia risk factors: The role

Vascular dementia risk factors: The role of /INS;diabetes and hypertension among younger-old and older-old patients

✍ Zandi, T. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 78 KB

19: The role of inflammation in diabetes

19: The role of inflammation in diabetes and vascular disease

📂 Article 📅 2008 🏛 Elsevier 🌐 English ⚖ 79 KB

The long-term efficacy and tolerability

The long-term efficacy and tolerability of donepezil in patients with vascular dementia

✍ David Wilkinson; Gustavo Róman; Stephen Salloway; Jane Hecker; Karyn Boundy; Din 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB 👁 2 views

## Abstract ## Objective To determine the long‐term tolerability and efficacy of donepezil in patients with vascular dementia (VaD). ## Methods International, multicentre, open‐label, 30‐week extension study of two 24‐week, randomised, double‐blind, placebo‐controlled studies. Participants were